Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.
Trial locations(19 sites)
China
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing Municipality Chinese PLA General Hospital, Beijing, Beijing Municipality The Third Affiliated Hospital of Sun Yat-sen University, Yuedong Hospital, Meizhou, Guangdong Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Cangzhou, Hebei Peking University Third Hospital Qinhuangdao Hospital, Qinhuangdao, Hebei Hebei Provincial People's Hospital, Shijiazhuang, Hebei Tangshan Worker's Hospital, Tangshan, Hebei First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang The first affiliated hospital of zhengzhou university, Zhengzhou, Henan Taihe Hospital, Shiyan, Hubei Zhongnan Hospital of Wuhan University, Wuhan, Hubei Baotou Central Hospital, Baotou, Inner Mongolia Nanjing First Hospital, Nanjing, Jiangsu Jining First People's Hospital, Jining, Shandong Liaocheng People's Hospital, Liaocheng, Shandong The Affiliated Hospital of Qingdao University, Qingdao, Shandong Weifang People's Hospital, Weifang, Shandong Chongqing General Hospital, Chongqing Huashan Hospital, Fudan University, Shanghai